A Morgan Cheatham Capitalist Capitalist Jim Breyer to lead health care and AI strategy

Breyer Capital makes a bold bet on the future of healthcare and life sciences

Breyer Capital has called Morgan Cheatham as a partner and head of healthcare and life sciences, marking a significant step forward in the business strategy to promote discoveries in Biomedical and Health Care AI. Cheatham participates by Bessemer Venture Partners, where he served as Vice President and the youngest director of the Board of Directors in the company’s history.

Meet Polymath VC with white coat

Cheatham brings an unusual perspective to business capital. He is soon MD from Brown’s Warren Alpert Medical School and a notable AI researcher who recently won one of just two points in the nation’s top pediatric-genetic program at Harvard/Boston Children’s Hospital. He also works in the editorial team at Nejm AI. As a rare hybrid of a doctor, computer science and investor, Cheatham is uniquely equipped to bridge the traditionally covered worlds of health care and biomedical discovery.

From bed to meeting room: Cheatham’s trip to Breyer Capital

Cheatham first met with legendary investor Jim Breyer a decade ago at Brown University, when Breyer spoke to an entrepreneurship class about which Cheatham was a teaching assistant. “This meeting was shaped by the bow of my career,” Ceatham says. “It was the first time I had heard someone make a bigger vision of how calculation and investment could reshape medicine on a non -linear scale, became fascinated by this vision and decided to continue Venture’s capital after the degradation.

“It was the first time I had heard someone make a bigger vision of how calculation and investment could reshape medicine on a non -linear scale.” – Morgan Cheatham, at Jim Breyer meeting

Cheatham continued to become Vice President of Bessemer Venture Partners, where he led the healthcare AI dissertation and comes from an early -stage dozen, including Ubridge and Hinge Health. He also helped to benefit and launch a cardiological business and served as a temporary chief executive at a rapidly growing telemedicine company, increasing revenue by 200% in nine months. Contributed to Bessemer’s Biotechnology Practice and founded Decoding. Cheatham also started initiatives like Deep health program and the authoring frameworks such as “10 Laws of Health Care” and “Six checks for the first companies”. Named in Forbes 30 under 30 list of business capital and is honored by NVCA in 2023.

Breyer lifts a strategic architect for the next chapter of health care

In Breyer Capital, Cheatham will lead to investment in healthcare and life sciences, focusing on computational methods and medical precision approaches. Its appointment highlights Breyer Capital’s deeper commitment to transformation innovation in the field of health care at the intersection of AI and Biomedical.

“It brings clinical insight, business experience and a sharp eye for transformative science.” – Jim Breyer, in Morgan Cheatham

Jim Breyer’s historic trillion of dollars

Jim Breyer, founder and chief executive of Breyer Capital, is one of Silicon Valley’s most successful VCs. It was a first investor in more than 40 companies that became public or acquired, including Facebook, where returns exceeded 100x.
Breyer has a strong personal and investment focus on the long -term bets on AI, quantum calculation and computational health care. It has been named #1 in the list of Top’s top Forbes Midas investors of Tech’s top investors and has won multiple Lifetime success awards in Venture Capital.

Not your standard portfolio

Breyer Capital is a global business that supports long -term investment, with ideas in all AI, Healthcare, Life Sciences, Consumer Tech and Enterprise. Its portfolio includes companies such as Meta (Facebook), Grammarly, Circle, Epic Games, legendary entertainment, Etsy and Spotify. The company invests using Breyer’s personal capital alongside the selected institutional co-investors.

Supporting the boldest ideas in biomedical

Since 2016, Breyer has forged deep links with research universities such as Stanford, Harvard, MIT, UCSF and UT Austin. In 2025, Breyer Capital He worked with the Harvard Medical School of Biomedical Informatics To support AI -powered medical accuracy, enhancing the leadership of the business in innovation in the field of healthcare.

“The future of medicine will be shaped not only by biology, but by the code.”

Breyer and Cheatham: A visionary collaboration based on experience and know -how

Breyer contributes to the generation investment experience, while Cheatham offers the know -how Deep Healthcare and AI. Their collaboration represents a rare combination of institutional perspective and next generation prospect.
Breyer Capital’s Health Care portfolio includes ARTERA, Atropos Health, Excellent, Repeat Health, Opadia, Sand and Sandboxaq. The business continues to focus on re -examining modern care infrastructure, supporting platforms in view of the software facing clinical needs.

Why Breyer believes that the next discoveries of medicine will be shaped by code

“We are excited to welcome Morgan to the team,” Jim Breyer said. “It brings clinical insight, business experience and a sharp eye for transformative science.”
Cheatham added that “scientific and technological progress goes beyond the evolution of health care. I am excited to invest in the next generation of companies born in convergence of discovery, clinical need and institutional change”.
The lease reflects Breyer Capital’s growing belief that the future of medicine lies in code -based discoveries.